Report Snapshot

Eisai

• Eisai is a pharmaceutical company operating globally with therapeutic focus on neurology and oncology.
• Eisai’s revenue in FY2019 increased by 8.2% mainly due to continuous significant growth of the anticancer agent Lenvima in all regions.
• Eisai compares favorably to most peers over near-term (2019–24) and to all peers over long-term (2024–29) revenue growth rates; the company is also expected to generate more than 22% of revenue from launch products in 2025, which again is higher than peer average.
• Eisai’s topline revenue is expected to show healthy growth through 2029 to offset pressure from generic competition. The company’s revenue is expected to increase primarily due to additional indications of its global brand Lenvima and launch of Dayvigo in Japan and the US.
• Eisai expects a decrease in revenue of pain treatment agent Lyrica due to generic competition. An invalidation trial has been requested regarding the Japanese method-of-use patent for Lyrica (being jointly promoted with Pfizer) that is scheduled to expire in 2022.
• Eisai expects to generate long-term growth in central nervous system portfolio primarily driven by its Alzheimer’s disease product, aducanumab.
• Eisai anticipates revenue growth in the US due to expansion of target indications of Lenvima (lenvatinib) plus Keytruda (pembrolizumab) combination for the treatment of patients with endometrial carcinoma.
• Lenvima revenue in the US will peak in 2026 and then decline due to its loss of exclusivity in the US in 2027.
• Fycompa revenue is expected to be driven by the launch of a new fine granule formulation in Japan.
• In November 2020, Eisai and Wren Therapeutics entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target α-synuclein for the potential treatment of synucleinopathies including Parkinson’s disease and dementia with Lewy bodies.